Fresenius Medical Care AG & Co. KGaA and Joslin Diabetes Center Partner to Improve Health of Patients with Diabetic Kidney Disease
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Schlagwort(e):
Sonstiges
Fresenius Medical Care AG & Co. KGaA and Joslin Diabetes Center
Partner to Improve Health of Patients with Diabetic Kidney Disease
15.04.2014 / 08:28
---------------------------------------------------------------------
Bad Homburg, Germany - Fresenius Medical Care AG & Co. KGaA (the "company"
or "Fresenius Medical Care"; Frankfurt Stock Exchange: FME / New York Stock
Exchange: FMS), the world's largest provider of dialysis products and
services, and Joslin Diabetes Center, Inc., the world's preeminent diabetes
research, clinical care and education organization, announced an agreement
today to jointly develop renal care programs in select Joslin Affiliated
Centers for patients with diabetic kidney disease (DKD).
Fresenius Medical Care and Joslin will jointly develop clinical guidelines
and effective care delivery systems to manage high blood pressure, glucose,
and nutrition in patients with DKD. In addition, the organizations will
help educate patients as they prepare for the possibility of end stage
renal disease (ESRD) and the necessity for dialysis or kidney
transplantation. Fresenius Medical Care and Joslin's multidisciplinary and
coordinated approach to chronic disease management will seek to improve
patient outcomes while reducing unnecessary or lengthy hospitalizations,
drug interactions and overall morbidity and mortality associated with
uncoordinated care.
"Identifying and treating individuals with chronic kidney disease,
especially those with diabetes, as early as possible can help us improve
health outcomes for patients and lower costs for the health care system,"
said Ron Kuerbitz, chief executive officer of Fresenius Medical Care North
America. "But even more exciting is what this research can mean for the
future. We hope that bringing together the world leaders in diabetes
research and kidney care will lay the foundation for future therapeutic
breakthroughs."
"We are excited to partner with Fresenius Medical Care," said John L.
Brooks III, President and CEO of Joslin Diabetes Center. "Kidney disease is
one of the most devastating complications of diabetes. Together with
Fresenius Medical Care we hope to make real progress in improving the care
of patients with DKD."
Chronic kidney disease (CKD) and ESRD combined are estimated to affect more
than 13% of the U.S. population, and diabetes is one of the leading causes
of ESRD. The Centers for Disease Control estimates that one in three adults
in this country will have diabetes by 2050 if today's trends continue.
These alarming statistics underscore the importance of the Fresenius
Medical Care - Joslin collaboration and the development of clinical
guidelines to manage care for patients who have both of these complex,
chronic diseases.
About Fresenius Medical Care
Fresenius Medical Care is the world's largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.5 million
individuals worldwide. Through its network of 3,250 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatments for 270,122 patients around the
globe. Fresenius Medical Care is also the world's leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products. For more information about Fresenius Medical Care,
visit the company's website at www.fmc-ag.com.
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes
research, clinical care, education and health and wellness programs on a
global scale. Joslin is dedicated to ensuring that people with diabetes
live long, healthy lives and offers real progress in preventing and curing
diabetes. Joslin is an independent, nonprofit institution affiliated with
Harvard Medical School, and is recognized worldwide for driving innovative
solutions in diabetes prevention, research, education, and care. Our
mission is to prevent, treat and cure diabetes. Our vision is a world free
of diabetes and its complications. For more information, visit
www.joslin.org.
Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
Ende der Corporate News
---------------------------------------------------------------------
15.04.2014 Veröffentlichung einer Corporate News/Finanznachricht,
übermittelt durch die DGAP - ein Unternehmen der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber
verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,
Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap-medientreff.de und
http://www.dgap.de
---------------------------------------------------------------------
Sprache: Deutsch
Unternehmen: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Deutschland
Telefon: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-Mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Indizes: DAX
Börsen: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE
Ende der Mitteilung DGAP News-Service
---------------------------------------------------------------------
263240 15.04.2014